Northwest Biotherapeutics Announces That Dr. Linda Liau Has Joined The Company's Scientific Advisory Board
Northwest Biotherapeutics Announces That Dr. Linda Liau Has Joined The Company's Scientific Advisory Board
BETHESDA, Md., Sept. 12, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, announces that Dr. Linda Liau, MD, PhD, MBA has joined the Company's Scientific Advisory Board (SAB).
马里兰州贝塞斯达，2023年9月12日 /PRNewswire/ — 开发DCVax实体瘤个性化免疫疗法的生物技术公司西北生物制药公司（OTCQB：NWBO）（“NW Bio”）宣布，医学博士、工商管理硕士琳达·廖博士已加入该公司的科学顾问委员会（SAB）。
Dr. Liau served as the Principal Investigator of the Phase 3 trial of DCVax-L for treatment of glioblastoma. She is Chair of the Department of Neurosurgery at UCLA, Professor and Director of the UCLA Brain Tumor Program. Dr. Liau is the former Editor-in-Chief of the Journal of Neuro-Oncology. She is the Director of the UCLA Brain Cancer SPORE (Specialized Program of Research Excellence). She is an elected member of the National Academy of Medicine.
廖博士曾担任用于治疗胶质母细胞瘤的DCVAX-L三期试验的首席研究员。她是加州大学洛杉矶分校神经外科系主任，加州大学洛杉矶分校脑肿瘤项目教授兼主任。廖博士是《神经肿瘤学杂志》的前主编。她是加州大学洛杉矶分校脑癌SPORE（专业卓越研究项目）的主任。她是美国国家医学院的民选成员。
The longstanding members of the Company's Scientific Advisory Board include Dr. Samir Khleif, Dr. Jerome Galon and Dr. John Smyth, and also included Dr. Mac Cheever for many years until his passing.
公司科学顾问委员会的长期成员包括萨米尔·赫莱夫博士、杰罗姆·加隆博士和约翰·史密斯博士，还包括麦克·切弗博士在他去世之前工作了多年。
Linda Powers, NWBio CEO, commented: "We are delighted to have Dr. Liau join our existing distinguished SAB. Her experience as a leader in the neuro-oncology field, her decades of research and knowledge of both brain cancer biology and immunotherapies, and her extensive experience with DCVax-L as the Principal Investigator of the Phase 3 trial, will be invaluable as we work together on DCVax-L approval and on future clinical programs building on that."
NWBio首席执行官琳达·鲍尔斯评论说：“我们很高兴廖博士加入我们现有的杰出SAB。她作为神经肿瘤学领域领导者的经验、她数十年的脑癌生物学和免疫疗法研究和知识，以及她作为3期试验首席研究员在DCVAX-L方面的丰富经验，将是我们共同努力获得DCVAX-L批准以及在此基础上开展未来临床计划的宝贵经验。”
About Northwest Biotherapeutics
关于西北生物治疗公司
Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both North America and Europe. The Company has a broad platform technology for DCVax dendritic cell-based vaccines. The Company's lead program is a 331-patient Phase III trial of DCVax-L for newly diagnosed Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal form of brain cancer, and is an "orphan disease." This Phase III trial has been completed, and the results have been presented in scientific meetings and published in JAMA Oncology. The Company has also developed DCVax-Direct for inoperable solid tumor cancers. It has completed a 40-patient Phase I trial and, as resources permit, plans to pursue Phase II trials. The Company previously conducted a Phase I/II trial with DCVax-L for advanced ovarian cancer together with the University of Pennsylvania.
Northwest Biotherapeutics是一家生物技术公司，专注于开发个性化免疫疗法产品，旨在在北美和欧洲比目前的治疗更有效地治疗癌症，没有与化疗相关的毒性，并且具有成本效益。该公司为基于DCVax树突状细胞的疫苗拥有广泛的平台技术。该公司的主要项目是一项针对新诊断的多形胶质母细胞瘤（GBM）的DCVAX-L的331名患者的III期试验。GBM 是最具侵略性和致命性的脑癌，是一种 “孤儿病”。该III期试验已经完成，结果已在科学会议上公布并发表在《JAMA Oncology》上。该公司还针对无法手术的实体瘤癌开发了DCVAX-Direct。它已经完成了一项40名患者的I期试验，并计划在资源允许的情况下进行II期试验。该公司此前曾与宾夕法尼亚大学一起使用DCVax-L进行了一项针对晚期卵巢癌的I/II期试验。